Relative Impact of Monotherapies for Vitiligo: A Network Meta‐Analysis Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70078 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Vitiligo, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta‐analysis has investigated the relative effect of vitiligo on relevant monotherapies.
Aim
The current study determined the relative effect of monotherapies for vitiligo through network meta‐analyses ( NMAs ).
Methods
The peer‐reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.
Results
The retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors ( JAKIs ), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve ( SUCRA ) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event ( AE ) at 6 months.
Conclusions
No significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A ( PUVA ) and narrow band ultraviolet B ( NB ‐ UVB ) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
- Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, University of Bordeaux, CNRS UMR 5164, ImmunoConcept, Bordeaux, France.
- Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
- School of Pharmacy, BRAC University, Merul Badda, Dhaka, Bangladesh.
ORCID-Profile: Aditya K Gupta, Mesbah Talukder
Zitieren
APA
Gupta, A. K., Bamimore, M. A., Seneschal, J., Piguet, V., & Talukder, M. (2025). Relative Impact of Monotherapies for Vitiligo: A Network Meta‐Analysis Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70078
Vancouver
Gupta AK, Bamimore MA, Seneschal J, Piguet V, Talukder M. Relative Impact of Monotherapies for Vitiligo: A Network Meta‐Analysis Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70078
BibTeX
@article{Gupta2025,
author = {Gupta, Aditya K and Bamimore, Mary A and Seneschal, Julien and Piguet, Vincent and Talukder, Mesbah},
title = {Relative Impact of Monotherapies for Vitiligo: A Network Meta‐Analysis Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70078}
}
EUVIMED